Skip to Main content Skip to Navigation
Journal articles

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis , on behalf of the Groupe Francophone des Myélodysplasies

Abstract : CD95, a member of the death receptor family initiates a caspase-dependent apoptosis, when activated by its ligand CD95L, thought to negatively regulate erythrocyte production in the bone marrow. We have previously shown that CD95 is overexpressed in two thirds of patients with a lower risk myelodysplastic syndrome (MDS) and that resistance to erythropoiesis-stimulating agents (ESA) is linked to poor residual erythropoiesis. In the present study, we show that CD95 overexpression and previous transfusion are independent predictive factors of ESA resistance. To investigate an alternative therapeutic strategy of anemia in ESA-resistant patients, we have conducted a preclinical study of the effects of APG101, a fusion protein consisting of the extracellular domain of human CD95 and the Fc region of human IgG1 on MDS erythropoiesis in vitro. APG101 increases the number of burst-forming unit-erythroid (BFU-E) progenitors derived from CD34 + progenitors in liquid culture and improves overall proliferation rate of erythroid precursors by inhibiting apoptosis. APG101 rescues BFU-E growth in MDS patients presenting with attrition of erythroid progenitors at baseline, independently of CD95 or CD95L expression level. Our data show that overexpression of CD95 at diagnosis is a hallmark of ESA resistance and that severe impairment of erythropoiesis is predictive of erythroid response to APG101 in vitro. These data provide a rationale for further clinical investigation of APG101 in an attempt to treat anemia in lower risk MDS patients.
Document type :
Journal articles
Complete list of metadatas

Cited literature [36 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01292986
Contributor : Mireille Bos <>
Submitted on : Thursday, March 24, 2016 - 10:15:44 AM
Last modification on : Thursday, April 9, 2020 - 11:54:08 AM
Long-term archiving on: : Monday, November 14, 2016 - 3:41:20 AM

File

7469-113612-4-PB.pdf
Publisher files allowed on an open archive

Identifiers

  • HAL Id : inserm-01292986, version 1
  • PUBMED : 26910909

Collections

Citation

Anna Raimbault, Cecile Pierre-Eugene, Alexandra Rouquette, Celine Deudon, Lise Willems, et al.. APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis , on behalf of the Groupe Francophone des Myélodysplasies. Oncotarget, Impact journals, 2016. ⟨inserm-01292986⟩

Share

Metrics

Record views

287

Files downloads

171